Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SGLT2i in CRS
NCT06111768Phase 2Completed
- Sponsor
- Yale University
- Start
- May 2024
- Primary completion
- Sep 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of dapagliflozin in cardiorenal syndrome (CRS) (2 arms), sponsored by Yale University. Primary endpoints: Percentage of eligible versus consented patients at 2 years, Percentage of enrolled patients with completed sample collections at 2 years and 1 more. Started May 2024; status: completed.
02
Drugs
dapagliflozin
03
Conditions
cardiorenal syndrome (CRS)
Beyond the preview
Go deeper on NCT06111768.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06111768.